Via practica 1/2018

Current options of conservative treatment of benign hyperplasia of prostate

Benign hyperplasia of prostate (BHP), sometimes referred to as benign prostatic enlargement (BPE), is frequent cause of bladder outflow obstruction (BOO) and one of the common diseases to affect older men. Histological disease (microscopic BHP) is present in more than 60 % of men in their sixties, and over 40 % of men beyond this age have lower urinary tract symptoms (LUTS); about half of this group has an impaired quality of life. The prevalence of BHP increases with age, and thus the absolute number of patients affected is rising worldwide as a result of aging populations. The main aim of conservative therapy in LUTS/BHP is to improve bothersome LUTS, restore an acceptable quality of life, and to identify patients at risk of disease progression in order to avoid an unfavorable outcome, such as acute urinary retention, etc. In this article is provided a brief overview of current options and opinions on conservative treatment of LUTS in men.

Keywords: benign hyperplasia of prostate, conservative treatment, monotherapy, combination therapy